In this episode we are focusing on cancer, oncolytic viruses and how investor mindset helps building successful biotech companies. Our guest today is Arthur Kuan, the CEO of CG Oncology. Arthur is a molecular biologist by training. After completing his undergraduate training, Arthur started his career as a venture investor working at several prominent Shanghai-based funds focusing on the Healthcare industry. In 2016, Arthur became the CEO of CG Oncology, one of the portfolio companies of Ally Bridge, the investment fund he was working at the time. In this interview, Arhtur shares his story of becoming a CEO and explains the challenges of bringing a promising scientific idea into clinics.

Together with Arthur we discussed:
◦ Arthur’s journey from investor to CEO
◦ The place of oncolytic viruses on the map of cancer therapeutics
◦ Combinational therapies for cancer
◦ Partnerships between emerging biotech startups and large pharma
◦ Differences in the mindset between investors and founders
◦ What it takes to lead a successful biotech company today
◦ Arthur’s vision for the future of personalized cancer treatment

Get in touch with Arthur:
◦ Twitter: https://twitter.com/cgoncology, https://twitter.com/KuanArthur
◦ LinkedIn: https://www.linkedin.com/in/arthurkuan/
◦ Web (CG Oncology): https://www.cgoncology.com/

Make sure to download the full show notes with our guest's bio, links to their most notable work, and our recommendations for further reads on the topic of the episode at pmedcast.com